Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
TransCode Therapeutics ( (RNAZ) ) has provided an update.
TransCode Therapeutics has announced a 1-for-33 reverse stock split aimed at boosting its stock price to meet Nasdaq’s minimum bid requirements. This split, effective December 4, 2024, will consolidate every 33 shares into one, streamlining the number of shares from over 17 million to approximately 523,202. The move, expected to affect all shareholders equally, comes as part of TransCode’s strategy to maintain its Nasdaq listing, with no fractional shares being issued as shares will be rounded up.
For an in-depth examination of RNAZ stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- ZMI, TBAL: 2 Canadian Balanced ETFs to Shield Your Returns
- Class Action Lawsuit Against Paragon 28, Inc. (NYSE:FNA)
- 3 Penny Stocks to Watch Now, 11/29/24
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
